• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Prostate PET Tracer PSMA-1007 Shows Bladder Activity Comparable to PSMA-11

by
November 13, 2026
in Health
Reading Time: 6 mins read
0
Prostate PET Tracer PSMA-1007 Shows Bladder Activity Comparable to PSMA-11

Prostate PET Tracer PSMA-1007 Shows Bladder Activity Comparable to PSMA-11

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A retrospective comparative study evaluating prostate cancer radiotracers for positron emission tomography has found that fluorine-18-labeled PSMA-1007 frequently produces urinary bladder activity matching that of gallium-68-labeled PSMA-11 combined with hydration and forced diuresis. In an analysis of 232 patients examined at a Swiss medical center, investigators determined that intravesical radioactivity from the fluorine-based tracer did not differ significantly from bladder activity recorded ninety minutes after administering the gallium tracer alongside oral hydration and intravenous furosemide. Furthermore, approximately one-quarter of the patients receiving the fluorine-18 radioligand exhibited high urinary bladder tracer concentrations exceeding a mean standardized uptake value of 7, a threshold typically associated with malignancy. Despite expectations of minimal renal elimination, this substantial bladder accumulation frequently risked obscuring local recurrences adjacent to the bladder wall.

Diagnostic imaging targeting the prostate-specific membrane antigen has become an essential clinical standard for evaluating prostate cancer across disease stages. Various clinical radioligands targeting this antigen demonstrate broadly comparable detection rates for malignant lesions but differ in their off-target distribution and bodily routes of clearance. Traditional radiotracers like gallium-68-labeled PSMA-11 rely heavily on renal elimination, which inevitably deposits substantial radioactive tracer into the urinary bladder during routine diagnostic scans. This intense accumulation produces pronounced image spillover that can physically mask pathological structures immediately adjacent to the bladder neck and prostatectomy bed. To resolve this challenge, clinical centers historically adopted patient preparation protocols that combine high-volume oral hydration with diuretic medications like furosemide to accelerate urinary clearance and wash radioactive content out of the urinary tract before scanning begins.

The development of fluorine-18-labeled PSMA-1007 offered a potential logistical and diagnostic alternative designed to bypass rapid renal elimination. Furthermore, early investigations established that this radiofluorinated compound undergoes predominantly hepatobiliary excretion rather than clearance through the urinary system. This metabolic pathway suggested that imaging with the fluorine-18 tracer would largely eliminate bladder spillover artifacts, improving the visualization of perivesical tumors without requiring patient hydration or diuretic administration. However, emerging clinical observations revealed substantial individual variability in bladder tracer accumulation. These contrasting observations prompted the nuclear medicine research team in Bern to conduct a direct retrospective investigation assessing the actual intravesical activity profiles of both radiopharmaceuticals in routine practice.

The investigation received formal institutional approval from the Cantonal Ethics Committee of Bern under research registry file number 2020-01162, remaining fully compliant with Swiss privacy and data protection legislation. The study cohort comprised consecutive prostate cancer patients undergoing clinical imaging between October 2018 and May 2020 who met the chronological inclusion criteria. In total, 232 patients were evaluated after receiving either gallium-68-labeled PSMA-11 or fluorine-18-labeled PSMA-1007. One hundred and thirty-two patients underwent imaging with the gallium-68 tracer alongside established hydration and diuresis protocols, while an independent cohort of one hundred patients received the radiofluorinated tracer without supplementary hydration or diuretics. Clinical baseline variables, initial tumor stages, histological Gleason scores, previous prostatectomy or radiation therapies, and serum prostate-specific antigen measurements were extracted from electronic records for detailed comparative analysis.

Both radiopharmaceuticals were obtained commercially from SWAN Isotopen AG in Bern and administered via intravenous bolus injection. Tomographic imaging was performed on a Siemens Biograph Vision 600 scanner using continuous bed motion preceded by low-dose attenuation computed tomography from vertex to mid-thighs. Patients examined with gallium-68-labeled PSMA-11 were orally hydrated with one liter of water thirty minutes post-injection, followed by an intravenous injection of twenty milligrams of furosemide at sixty minutes. In this cohort, seventy-six patients were imaged at ninety and one hundred and fifty minutes, while fifty-six received an additional ten milligrams of furosemide at one hundred and twenty minutes post-injection. Conversely, the one hundred patients scanned with fluorine-18-labeled PSMA-1007 received no hydration or diuretics, undergoing imaging approximately one hundred and twenty minutes post-injection.

Images were iteratively reconstructed with vendor software using ordered subset expectation maximization with time-of-flight information, five subsets, four iterations, a 440 by 440 matrix, four-millimeter slice thickness, and post-reconstruction two-millimeter Gaussian filtering. Datasets were analyzed in Syngo.Via workstations to extract quantitative metrics. Urinary bladder content was characterized by measuring the mean standardized uptake value within defined volumes of interest. For pathological findings, maximum and peak standardized uptake values were determined in locally recurrent lesions and locoregional lymph node metastases using an automated forty percent intensity threshold isocontour tool. When bladder segmentation was hindered by adjacent bowel activity or minimal intraluminal tracer, a spherical volume of interest was manually placed within the bladder lumen to ensure rigorous, standardized measurement across all patient scans.

Statistical analyses were conducted in IBM SPSS Statistics Version 25, setting the significance threshold at 0.05 after Bonferroni correction for multiple testing. Uptake distributions were formally tested using the Kolmogorov-Smirnov test. Spearman rank correlation evaluated relationships between bladder accumulation, patient characteristics, and lesion-to-bladder ratios. Between-group differences across clinical classifications were evaluated using non-parametric Kruskal-Wallis analysis of variance. Through these statistical procedures, the researchers tested whether gallium-68 administration with furosemide diuresis produced lower bladder activity and higher tumor-to-urine contrast compared with fluorine-18 without diuresis. The analytical framework specifically focused on defining population-level distribution curves to distinguish consistent predictable clearance from skewed distributions containing problematic extreme outliers in clinical cohorts. In addition, exploratory evaluations assessed whether specific tumor stages, clinical factors, or patient demographics were associated with elevated urinary excretion of the radiofluorinated tracer.

Quantitative evaluation showed that intravesical activity followed distinct mathematical distributions for each radiotracer. For gallium-68-labeled PSMA-11, bladder mean standardized uptake values at ninety minutes post-injection ranged from 1.2 to 79.9, with a median of 5.2 and an interquartile range of 3.7 to 6.7, conforming to a normal distribution. For fluorine-18-labeled PSMA-1007, bladder activity ranged widely from 0.42 to 25.8, with a median of 3.6 and an interquartile range of 1.7 to 7.1, following an exponential distribution. Crucially, non-parametric comparison revealed that bladder activity ninety minutes after gallium-68 injection did not differ significantly from fluorine-18 activity recorded at one hundred and twenty minutes, yielding a probability value of 0.16. Although half the fluorine-18 patients showed urinary values below 4.0, a broad distribution tail demonstrated that approximately twenty-five percent exhibited high bladder accumulation exceeding a mean standardized uptake value of 7.0.

The elevated bladder activity observed in a substantial proportion of fluorine-18 patients directly impacted diagnostic tumor-to-background contrast. Among the one hundred patients scanned with fluorine-18-labeled PSMA-1007, local recurrence was detected in seventy-four patients, exhibiting a median maximum standardized uptake value of 10.2 and a median peak value of 4.8. Notably, bladder mean standardized uptake values exceeded tumor maximum uptake in seventeen percent of patients, and exceeded peak uptake in twenty-eight percent. In fifty-two patients with suspected regional lymph node metastases, bladder activity surpassed maximum lymph node uptake in seven percent and peak uptake in thirteen percent. When intraluminal urine radioactivity surpasses surrounding pathological uptake, intense physical spillover and partial-volume artifacts can completely obscure recurrent tumor tissue, introducing an acute vulnerability for false-negative interpretations in anatomical areas directly bordering the bladder.

In their exploratory analysis, the investigators examined whether patient clinical characteristics could explain or predict which individuals developed high urinary accumulation with fluorine-18-labeled PSMA-1007. Kruskal-Wallis testing demonstrated no statistically significant differences in urinary mean standardized uptake values across initial tumor stages, regional nodal stages, or surgical margin statuses. Furthermore, previous clinical treatments, including radical prostatovesiculectomy, external radiotherapy, or combined modalities, showed no correlation with urinary activity levels. Historical Gleason scores also failed to correlate with bladder accumulation. In addition, non-parametric Spearman rank testing revealed no statistically significant correlation between urinary tracer concentration and patient age, administered radioactive dose, or serum prostate-specific antigen concentration. These findings indicate that elevated urinary elimination of fluorine-18-labeled PSMA-1007 occurs unpredictably in clinical practice, preventing physicians from anticipating problematic bladder activity based on standard patient records.

The authors highlighted the practical implications of these diagnostic challenges through a detailed case report of an eighty-one-year-old male evaluated for biochemically recurrent disease following previous radical prostatectomy. Under default clinical display windowing using a hot-metal color scale ranging from zero to five standardized uptake units, intense urinary activity completely concealed local disease within the bladder wall. Only upon expanding the window display scale up to twenty standardized uptake units did the fused tomographic image reveal an intramural recurrence in the urinary bladder wall. Conversely, the authors presented an illustrative seventy-five-year-old patient evaluated with gallium-68-labeled PSMA-11 under furosemide diuresis, where minimal urinary activity permitted clear visual identification of an infundibular recurrence. These clinical cases underscore that high urinary accumulation of fluorine-18-labeled PSMA-1007 can actively conceal malignant lesions unless readers modify viewing windows.

The authors noted several important study limitations and outlined critical considerations for clinical imaging protocols. Because the research relied on retrospective records, an active cohort examining fluorine-18-labeled PSMA-1007 with forced diuresis was not available, as diuretics were not standard clinical practice for this tracer. Additionally, the cohort lacked comprehensive histological confirmation for every suspected lesion, relying on the established high positive predictive value of PSMA-targeted positron emission tomography. The researchers also observed that delayed gallium-68 acquisitions at one hundred and fifty minutes showed increased bladder activity that was not fully suppressed by an additional ten milligrams of furosemide, suggesting that higher secondary diuretic doses may be necessary. Ultimately, the authors concluded that prospective randomized trials are needed to assess whether hydration and diuresis protocols can mitigate unpredictable bladder accumulation with fluorine-18-labeled PSMA-1007 and optimize perivesical lesion detection.

Subject of Research: Comparison of urinary bladder radiotracer activity between [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in prostate cancer PET/CT

Article Title: Comparison of urinary bladder activity from [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in patients with prostate cancer undergoing PSMA-ligand PET/CT

Article References: Krieger, K., Cumming, P., Alberts, I. L., Rominger, A. O., & Afshar-Oromieh, A. (2026). Comparison of urinary bladder activity from [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in patients with prostate cancer undergoing PSMA-ligand PET/CT. EJNMMI Reports, 10(1), Article 5. https://doi.org/10.1186/s41824-026-00286-8

Image Credits: AI Generated

DOI: 10.1186/s41824-026-00286-8

Keywords: prostate cancer, PET/CT imaging, [68Ga]Ga-PSMA-11, [18F]PSMA-1007, PSMA radioligands, urinary bladder activity, furosemide diuresis, perivesical lesions, biochemical recurrence, standardized uptake value, SUVmean, tumor-to-urine ratio, pelvic lymph node metastasis, hepatobiliary clearance, renal elimination, Siemens Biograph Vision 600, image segmentation

News Source: Nathaniel Bowman. (November 13, 2026). Prostate PET Tracer PSMA-1007 Shows Bladder Activity Comparable to PSMA-11. Scienmag.

Tags: biochemical recurrencefurosemide diuresishepatobiliary clearanceimage segmentationpelvic lymph node metastasisperivesical lesionsPET/CT imagingProstate CancerPSMA radioligandsrenal eliminationSiemens Biograph Vision 600standardized uptake valueSUVmeantumor-to-urine ratiourinary bladder activity[18F]PSMA-1007[68Ga]Ga-PSMA-11
Share12Tweet7Share2ShareShareShare1

Related Posts

Review Evaluates Herbal, MicroRNA, and Probiotic Experimental Therapies for Endometritis

Review Evaluates Herbal, MicroRNA, and Probiotic Experimental Therapies for Endometritis

November 16, 2026
Salmonella Lineage Crosses Poultry and Human Contacts in Urban Ghana Study

Salmonella Lineage Crosses Poultry and Human Contacts in Urban Ghana Study

November 16, 2026

Tuberculosis Care Delays Exceed Acceptable Limits Across Seven High-Burden Nations

November 16, 2026

Stage-Tailored Interventions Offer Preliminary Blood Pressure Reductions in Hypertension Meta-Analysis

November 16, 2026

POPULAR NEWS

  • Maintenance BCG Reduces Bladder Cancer Progression When Patients Overcome Treatment Barriers

    Maintenance BCG Reduces Bladder Cancer Progression When Patients Overcome Treatment Barriers

    29 shares
    Share 12 Tweet 7
  • High-Avidity BCMA CAR T-Cell Therapy Shows High Efficacy in AL Amyloidosis

    29 shares
    Share 12 Tweet 7
  • Zero Mass Limit in Karch-Randall Gravity Yields Decoupled Massive Vector Theory

    29 shares
    Share 12 Tweet 7
  • Kenyan Smallholder Farmers Classify Diverse Pasture Species for Sustainable Dairy Production

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Matrix Environment Directs Architecture and Lactation Programs in Human Milk Organoids

Continuous Cattail Bio-SAP Cores Decouple Water Absorption from Dimensional Swelling

Titanium Diboride Armor Shows Rapid Entropy Saturation Under Deuterium Plasma Bombardment

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.